Very early researchUnknownNCT04412889What this trial is testingBCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MMWho this might be right forMultiple Myeloma Hebei Yanda Ludaopei Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT07259070What this trial is testingMulticenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell LymphomaWho this might be right forDLBCLCLLFL+3 more Institute of Hematology & Blood Diseases Hospital, China 20
Early research (Phase 1)UnknownNCT03685786What this trial is testingCART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCTWho this might be right forLeukemia, Lymphocytic, Acute, B-CellLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell Shenzhen Second People's Hospital 20
Testing effectiveness (Phase 2)UnknownNCT02965092What this trial is testingCD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesWho this might be right forAcute Lymphoblastic LeukemiaB Cell Lymphoma Wuhan Sian Medical Technology Co., Ltd 80
Testing effectiveness (Phase 2)Looking for participantsNCT05281809What this trial is testingLocal Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaWho this might be right forB-Cell LymphomaB Acute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+6 more John Lister 30
Early research (Phase 1)Ended earlyNCT04142619What this trial is testingStudy Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)Who this might be right forRelapsed/Refractory Multiple Myeloma Cellectis S.A. 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT06480565What this trial is testingA Phase 1/2 Trial of ADI-270 in ccRCCWho this might be right forClear Cell Renal Cell Carcinoma Adicet Therapeutics 60
Early research (Phase 1)Ended earlyNCT03283631What this trial is testingIntracerebral EGFR-vIII CAR-T Cells for Recurrent GBMWho this might be right forRecurrent GlioblastomaRecurrent Gliosarcoma Gary Archer Ph.D. 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05982275What this trial is testingTrial of an Investigational Drug After Rejecting the Relapse of an Allogeneic TransplantWho this might be right forMultiple MyelomaAllogeneic Stem Cell Transplantation Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 25
Not applicableEnded earlyNCT03436771What this trial is testingLong-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductWho this might be right forNon Hodgkin LymphomaMultiple MyelomaChronic Lymphocytic Leukemia+3 more Juno Therapeutics, a Subsidiary of Celgene 4
Very early researchUnknownNCT04182581What this trial is testingBCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Xijing Hospital 18
Early research (Phase 1)Study completedNCT03338972What this trial is testingImmunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Looking for participantsNCT04422912What this trial is testingA Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Who this might be right forPemphigus Vulgaris Cabaletta Bio 40
Very early researchNot Yet RecruitingNCT07423572What this trial is testingClinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)Who this might be right forRefractory Idiopathic Membranous Nephropathy The First Affiliated Hospital of Zhejiang Chinese Medical University 18
Early research (Phase 1)Active Not RecruitingNCT03617198What this trial is testingCD4 CAR+ ZFN-modified T Cells in HIV TherapyWho this might be right forHiv University of Pennsylvania 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06777264What this trial is testingInaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1Who this might be right forAcute Lymphoblastic LeukemiaB Cell ALL First Affiliated Hospital of Zhejiang University 20
Early research (Phase 1)Active Not RecruitingNCT05631899What this trial is testingCAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid TumorsWho this might be right forSolid Tumor, AdultEphA2 OverexpressionKRAS G12V+2 more Chinese PLA General Hospital 9
Early research (Phase 1)Looking for participantsNCT06992583What this trial is testingTargeted Anti-CEA CAR-T Immunotherapy for Advanced Lung CancerWho this might be right forAdvanced Lung Cancer Chongqing Precision Biotech Co., Ltd 60
Early research (Phase 1)Not Yet RecruitingNCT07224568What this trial is testingCytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid TumorsWho this might be right forSolid Tumor (Excluding CNS)Hepatocellular CarcinomaLiver Cell Carcinoma+3 more Seattle Children's Hospital 21
Testing effectiveness (Phase 2)Looking for participantsNCT06064903What this trial is testingCD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LLWho this might be right forT-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Bambino Gesù Hospital and Research Institute 26